Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:analyzes |
clinical researchers
|
| gptkbp:chemicalFormula |
C20H25N3O4S
|
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:Australia gptkb:Canada gptkb:United_States Europe Phase 1 Phase 2 Phase 3 results published Phase 4 results negative results pending results positive |
| gptkbp:collaborations |
clinical research organizations
|
| gptkbp:developedBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:evaluates |
under investigation
|
| gptkbp:formulation |
solution
|
| gptkbp:future_plans |
clinical trials
|
| gptkbp:hasFocusOn |
complement-mediated disorders
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALXN1720
|
| gptkbp:isATypeOf |
1234567-89-0
|
| gptkbp:mandates |
autoimmune diseases
|
| gptkbp:marketSegment |
not approved
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
clinical development
preclinical |
| gptkbp:regulatoryCompliance |
under review
|
| gptkbp:research |
venture capital
government grants monoclonal antibody biologics private investors pharmaceutical funding |
| gptkbp:research_areas |
hematology
immunology |
| gptkbp:researchFocus |
complement-mediated diseases
|
| gptkbp:route |
intravenous
subcutaneous |
| gptkbp:safetyFeatures |
under investigation
|
| gptkbp:scientificName |
C5 complement protein
|
| gptkbp:sideEffect |
fatigue
headache nausea infusion reactions |
| gptkbp:sponsor |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:status |
investigational
|
| gptkbp:targets |
complement system
atypical hemolytic uremic syndrome paroxysmal nocturnal hemoglobinuria inhibition_of_C5_protein |
| gptkbp:triggerType |
complement inhibition
|